Table 2 Assessment of risk factors for differences in GRID2IP expression levels among different subgroups
Characteristic | Levels | Low expression of GRID2IP | High expression of GRID2IP | p |
|---|---|---|---|---|
n | Â | 322 | 322 | Â |
T stage, n (%) | T1 | 10 (1.6%) | 10 (1.6%) | 0.132 |
| Â | T2 | 61 (9.5%) | 50 (7.8%) | Â |
| Â | T3 | 222 (34.6%) | 214 (33.4%) | Â |
| Â | T4 | 28 (4.4%) | 46 (7.2%) | Â |
N stage, n (%) | N0 | 206 (32.2%) | 162 (25.3%) |  < 0.001 |
| Â | N1 | 75 (11.7%) | 78 (12.2%) | Â |
| Â | N2 | 38 (5.9%) | 81 (12.7%) | Â |
M stage, n (%) | M0 | 250 (44.3%) | 225 (39.9%) |  < 0.001 |
| Â | M1 | 28 (5%) | 61 (10.8%) | Â |
Pathologic stage, n (%) | Stage I | 58 (9.3%) | 53 (8.5%) |  < 0.001 |
| Â | Stage II | 142 (22.8%) | 96 (15.4%) | Â |
| Â | Stage III | 83 (13.3%) | 101 (16.2%) | Â |
| Â | Stage IV | 27 (4.3%) | 63 (10.1%) | Â |
Primary therapy outcome, n (%) | PD | 18 (5.8%) | 15 (4.8%) | 0.457 |
| Â | SD | 2 (0.6%) | 3 (1%) | Â |
| Â | PR | 5 (1.6%) | 11 (3.5%) | Â |
| Â | CR | 129 (41.3%) | 129 (41.3%) | Â |
Gender, n (%) | Female | 149 (23.1%) | 152 (23.6%) | 0.874 |
| Â | Male | 173 (26.9%) | 170 (26.4%) | Â |
Race, n (%) | Asian | 6 (1.5%) | 6 (1.5%) | 0.030 |
| Â | Black or African American | 24 (6.1%) | 45 (11.4%) | Â |
| Â | White | 164 (41.6%) | 149 (37.8%) | Â |
Age, n (%) |  ≤65 | 141 (21.9%) | 135 (21%) | 0.691 |
|  |  > 65 | 181 (28.1%) | 187 (29%) |  |
Weight, n (%) |  ≤ 90 | 122 (35.1%) | 122 (35.1%) | 0.091 |
|  |  > 90 | 41 (11.8%) | 63 (18.1%) |  |
BMI, n (%) |  < 25 | 60 (18.2%) | 47 (14.3%) | 0.047 |
|  |  ≥ 25 | 97 (29.5%) | 125 (38%) |  |
Height, n (%) |  < 170 | 76 (23.1%) | 83 (25.2%) | 1.000 |
|  | ≥170 | 81 (24.6%) | 89 (27.1%) |  |
Neoplasm type, n (%) | Colon adenocarcinoma | 240 (37.3%) | 238 (37%) | 0.928 |
| Â | Rectum adenocarcinoma | 82 (12.7%) | 84 (13%) | Â |
Colon polyps present, n (%) | No | 105 (32.5%) | 119 (36.8%) | 0.630 |
| Â | Yes | 50 (15.5%) | 49 (15.2%) | Â |
History of colon polyps, n (%) | No | 190 (34.2%) | 187 (33.7%) | 1.000 |
| Â | Yes | 90 (16.2%) | 88 (15.9%) | Â |
Lymphatic invasion, n (%) | No | 198 (34%) | 152 (26.1%) |  < 0.001 |
| Â | Yes | 90 (15.5%) | 142 (24.4%) | Â |
Residual tumor, n (%) | R0 | 235 (46.1%) | 233 (45.7%) | 0.136 |
| Â | R1 | 3 (0.6%) | 3 (0.6%) | Â |
| Â | R2 | 12 (2.4%) | 24 (4.7%) | Â |
CEA level, n (%) |  ≤ 5 | 140 (33.7%) | 121 (29.2%) |  < 0.001 |
|  |  > 5 | 56 (13.5%) | 98 (23.6%) |  |
Perineural invasion, n (%) | No | 89 (37.9%) | 86 (36.6%) | 0.193 |
| Â | Yes | 24 (10.2%) | 36 (15.3%) | Â |
OS event, n (%) | Alive | 268 (41.6%) | 247 (38.4%) | 0.049 |
| Â | Dead | 54 (8.4%) | 75 (11.6%) | Â |
DSS event, n (%) | Alive | 284 (45.7%) | 260 (41.8%) | 0.005 |
| Â | Dead | 27 (4.3%) | 51 (8.2%) | Â |
PFI event, n (%) | Alive | 250 (38.8%) | 229 (35.6%) | 0.071 |
| Â | Dead | 72 (11.2%) | 93 (14.4%) | Â |
Age, median (IQR) | Â | 68 (60, 76) | 68 (57, 75.75) | 0.445 |
Height, median (IQR) | Â | 170 (160.02, 175.2) | 170 (162.38, 179) | 0.421 |
Weight, median (IQR) | Â | 76 (64.1, 90.35) | 83 (67.2, 94.7) | 0.032 |
BMI, median (IQR) | Â | 26.67 (23.14, 30.42) | 27.4 (24.82, 33.15) | 0.038 |